Results 111 to 120 of about 1,677,629 (133)

0637 Composite Response with Once-Nightly Sodium Oxybate: Symptom Improvement in Participants with Narcolepsy Type 1

SLEEP
Abstract Introduction A novel once-nightly formulation of sodium oxybate (ON-SXB; LUMRYZ™) was investigated in patients with narcolepsy type 1 (NT1) and 2 (NT2) in the phase 3 REST-ON trial (NCT02720744).
Luis Ortiz, Thomas Roth, Anne Morse, Michael Thorpy, John Harsh, Clete Kushida, Jennifer Gudeman, Yves Dauvilliers   +7 more
openaire   +1 more source

LONG-TERM SAFETY OF ONCE-NIGHTLY SODIUM OXYBATE: INTERIM ANALYSIS OF DATA FROM RESTORE

Chest, 2022
THOMAS P STERN, ASIM ROY, COLIN M SHAPIRO, JOHN HARSH, AKINYEMI AJAYI, SALLY IBRAHIM, DAVID SEIDEN, JENNIFER GUDEMAN   +7 more
openaire   +1 more source

0757 Sleepiness Improvement With Once-Nightly Sodium Oxybate in Patients With and Without Prior Twice-Nightly Oxybate Use: Specialty Pharmacy Data Analysis

SLEEPJ
Abstract Introduction Once-nightly sodium oxybate (ON-SXB) is approved to treat cataplexy or excessive daytime sleepiness (EDS) in patients ≥7 years of age with narcolepsy. ON-SXB demonstrated significant improvements in both objective (Maintenance of Wakefulness Test) and subjective (Epworth ...
Laura Herpel, Michael Thorpy, Sarah Meskill, Chad Ruoff, Erin Buysman, Diana Carino, Michelle Vu, Brian Abaluck, Jennifer Gudeman   +8 more
openaire   +1 more source

0833 Long-Term Safety and Tolerability of Once-Nightly Sodium Oxybate: A Post Hoc Analysis from RESTORE

SLEEP
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) is an extended-release formulation of sodium oxybate that eliminates the second, middle-of-the-night dose required by immediate-release twice-nightly oxybate (TN-OXB) formulations.
Sally Ibrahim, John Harsh, Bruce Corser, J Douglas Hudson, Adrian Santamaria, Paula Schweitzer, Brian Abaluck, Jennifer Gudeman   +7 more
openaire   +1 more source

Pharmacokinetics of FT218, a Once-Nightly Sodium Oxybate Formulation in Healthy Adults

Clinical Therapeutics, 2021
David Seiden
exaly  

Randomized, crossover, open-label study of the relative bioavailability and safety of FT218, a once-nightly sodium oxybate formulation: Phase 1 study in healthy volunteers

Sleep Medicine, 2022
Richard Bogan, David Seiden, Jennifer Gudeman   +2 more
exaly  

Assessing Usability of Once-Nightly Sodium Oxybate Extended-Release Oral Suspension for Narcolepsy

Sleep Medicine
M. Lavender, E. Wermter, L.E. Ortiz, A.M. Morse, M. Horsnell, J. Gudeman   +5 more
openaire   +1 more source

Consistent Efficacy of Once-Nightly Sodium Oxybate on Disrupted Nighttime Sleep in People With Narcolepsy

Sleep Medicine
Y. Dauvilliers, M.J. Thorpy, T. Roth, C.A. Kushida, A.M. Morse, J. Harsh, L.E. Ortiz, J. Gudeman   +7 more
openaire   +1 more source

Improvement of Individual Excessive Daytime Sleepiness Symptoms With Once-Nightly Sodium Oxybate for Narcolepsy

Sleep Medicine
H. Merius, M.J. Thorpy, E. Wermter, C.A. Kushida, B. Abaluck, J. Gudeman   +5 more
openaire   +1 more source

Long-term safety and efficacy of extended-release once-nightly sodium oxybate for narcolepsy

Sleep Medicine
B.C. Corser, A.M. Morse, T. Stern, A.O. Ajayi, C.A. Kushida, J. Gudeman   +5 more
openaire   +1 more source